Porter Derrell's Form 4 filing
Acumen Pharmaceuticals, Inc. (ABOS) · filed Jun 17, 2026
- Accession no.
- 0001628280-26-043987
- Filed
- Jun 17, 2026
- Trade date
- Jun 15-17, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $75.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Porter DerrellCIK 0001706400 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Common Stock | MOption exerciseAcquired | +6,460 | $1.07 | +$6,912.2 | 54,760 | Direct | |
| Jun 15, 2026 | Common Stock | SSaleDisposed | −6,460 | $2.35 | −$15,181 | 48,300 | Direct | |
| Jun 16, 2026 | Common Stock | SSaleDisposed | −12,800 | $2.33F1 | −$29,824 | 35,500 | Direct | |
| Jun 17, 2026 | Common Stock | MOption exerciseAcquired | +13,040 | $1.07 | +$13,952.8 | 48,540 | Direct | |
| Jun 17, 2026 | Common Stock | SSaleDisposed | −13,040 | $2.33 | −$30,383.2 | 35,500 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Common Stock | MOption exerciseDisposed | −6,460 | $0.00 | $0 | 13,040 | Direct | |
| Jun 17, 2026 | Common Stock | MOption exerciseDisposed | −13,040 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.305 to $2.345. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.